If at first you don’t succeed in gene therapy, then try, try again. | If at first you don’t succeed in gene therapy, then try ...
After more than 10 years in development, Regeneron secured a landmark approval for its monoclonal antibody garetosmab, now ...
After receiving a checkered regulatory scorecard in 2024, Aurobindo’s sterile injectables and oncology unit is back in the ...
SK’s deal with India’s MSN Laboratories will allow the Korean company to extend its market exclusivity beyond October of 2032 ...
In their attempts to challenge the Medicare drug price negotiation program, introduced by former President Joe Biden under ...
After drafting plans for a phased expansion at its production campus in Swords, Ireland, back in 2022, CDMO SK Pharmteco this ...
With a massive array of prescription drugs losing patent protection in the coming years, including many biologics, Sandoz has ...
AstraZeneca reported positive results from two non-small cell lung cancer trials for Enhertu and an Orpathys-Tagrisso ...
With its latest trial readout for under-the-skin efgartigimod, argenx is adding another feather to the FcRn blocker’s cap. | ...
Biokin Pharma’s iza-bren, a first-in-class antibody-drug conjugate partnered with Bristol Myers Squibb, has posted another positive phase 3 readout. | Biokin Pharma’s iza-bren, a first-in-class ...
After a year of impairments, revenue downgrades and the ousting of its chief executive officer, Australian plasma and vaccine specialist CSL provided signs of recovery on Tuesday. In its fiscal 2026 ...
Pushing back on the concept that there can only be one victor among branded obesity drugmakers, Novo Nordisk CEO Mike Doustdar thinks that investors aren’t seeing the whole picture. As the massive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results